RIPK2 is highly expressed in paclitaxel-resistant ovarian cancer cell lines, and high RIPK2 expression is associated with paclitaxel resistance in plasmacytoid ovarian cancer [18]. Here, RIPK2 is linked to ovarian carcinoma.